StockNews.com Begins Coverage on Check-Cap (NASDAQ:CHEK)

Equities researchers at StockNews.com started coverage on shares of Check-Cap (NASDAQ:CHEK) in a research note issued on Sunday. The brokerage set a “sell” rating on the medical research company’s stock.

Check-Cap Stock Down 2.3 %

Shares of NASDAQ CHEK opened at $1.69 on Friday. The company has a market cap of $9.89 million, a P/E ratio of -0.56 and a beta of 0.39. Check-Cap has a 52 week low of $1.64 and a 52 week high of $4.63. The business has a 50-day simple moving average of $1.91 and a two-hundred day simple moving average of $2.11.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.